Clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies
The Company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T, TCR and allogeneic T cell therapies. Its lead product candidate, rivo-cel, is an allogeneic polyclonal T cell product that has shown promising results in reducing leukemia relapse after a stem cell transplant. Bellicum’s lead GoCAR-T candidate, BPX-601, is designed to be a more efficacious CAR-T cell product capable of overriding key immune inhibitory mechanisms.